With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU). Saint ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory ...

1 Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ® - Valneva 2 Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension ...

Chikungunya cases have spiked substantially in La Réunion since early 2025, with 8,600 cases recorded and almost 3,000 new cases during the week of March 3 to 9, 2025 1. Similar to the 2005-2006 ...

Valneva will work with local health authorities and wholesalers on the French island territory to distribute the vaccines.

Saint Herblain, France Tuesday, April 1, 2025, 16:00 Hrs [IST] ...

3 Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ® 4 Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine ...

Valneva will provide 40,000 doses of its chikungunya vaccine Ixchiq to French overseas territory La Réunion as part of efforts to curb the spike in disease cases on the island. Valneva confirmed ...

2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France's Island of ...

2 Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ® 3 Valneva Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, IXCHIQ® 4 ...

Valneva responds to French govt’s call for supply of chikungunya vaccine, Ixchiq: Saint Herblain, France Wednesday, March 26, 2025, 17:00 Hrs [IST] Valneva SE, a specialty vacci ...